Objective: A vagal nerve stimulator (VNS) is a FDA-approved device implanted for treatment of intractable epilepsy and major depression in adults and children. Recently, otolaryngologists are becoming more involved in the implantation and care of side effects for these devices.
Method: A retrospective chart review was performed. Our local surgical database was searched for cases of VNS implantation during a period of 40 months. Fourteen cases performed by otolaryngologists were identified. Medical records were then reviewed for outcomes including medication reduction, seizure frequency and duration, device-related complications, and surgical complications.
Results: Of the 14 cases performed by otolaryngologists over 40 months, 11 (78.6%) cases demonstrated either a decrease in medications required, seizure frequency, or duration. The most common side effect was voice alteration during device initiation. There were no early postsurgical complications.
Conclusion: These data provide support for the qualification of otolaryngologists for performing VNS implantation and monitoring postoperative and laryngeal side effects of the VNS.
General Otolaryngology P63-Mediated Cisplatin Resistance with Head and Neck Cancer
Taku Yamashita, MD, PhD (presenter); Bert O'Malley, MD; Daqing Li, MD; Shunsuke Miyamoto, MD Objective: 1) Understand the molecular pathway of cisplatinbased chemoresistance with head and neck cancer. 2) Investigate if p63 plays an important role in regulating MRE11/ RAD50/NBS1 (MRN) complex that contributes to cisplatinbased chemoresistance.
Method: Both JHU006 and JHU020 HNSCC cell lines were characterized as either sensitive or resistant to cisplatin. MRN and p63 expression levels were examined. The p63-mediated MRN regulation was studied by introducing mutant NBS1 and siRNA. Cell growth was evaluated in response to cisplatin treatment and regulation of p63 and MRN.
Results: IC50 to cisplatin for JHU006 and JHU020 was 8.76 and 0.61, respectively, suggesting that JHU006 is a cisplatin-resistant cell line. Increased expression levels of MRN were found after cisplatin treatment in JHU006 as compared with JHU020. The p63 expression level, which is a positive transcriptional factor for RAD50 and MRE11, was up-regulated after cisplatin treatment in JHU006 but not in JHU020. The knockdown of p63 resulted in the down-regulation of MRN, and therefore there were interrupted DNA repair and sensitized resistant tumor cells to cisplatin. The introduction of mutant NBS1 could down-regulate MRN, but was not effective on the p63 expression.
Conclusion:
Our study suggested that p63 may play an important role in regulating cisplatin-based chemoresistance via MRN. The understanding of the molecular pathway of cisplatinbased chemoresistance could help us to design an efficient treatment strategy for head and neck cancer.
General Otolaryngology Prevalence of Low Titers of Pneumococcal Antibodies
Constanza Beltran (presenter); Carolina A. Aranis; Eduardo Talesnik; Raimundo Garcia Objective: 1) Determine the prevalence of low titers of pneumococcal antibodies (PAB) in patients with recurrent infections. 2) Assess whether there is a difference in PAB titers between patients unimmunized and patients vaccinated against pneumococcus.
Method: Cross-sectional study between September 2006 and May 2008 in patients with recurrent infections. PAB levels against 10 serotypes were measured in all patients, and it was established if they had been vaccinated against pneumococcus. We compared the frequency of PAB low titers between both groups using the chi-square test.
Results: A total of 257 patients were included in the study, aged between 0 and 68 years (median: 5 years) and with 54% being male. Sixty-one patients (24%) were vaccinated against pneumococcus. The prevalence of low titers of PAB (more than 50% of the serotypes with levels lower than 1.3 ug/mL) was 43% overall, with 8.2% and 53.6% in vaccinated and unvaccinated patients, respectively (P < .0001).
Conclusion: Low levels of specific antibodies to pneumococcus is a common condition in patients with recurrent infections. It appears that the pneumococcal vaccine plays an important role in reducing the prevalence of this condition, but prospective studies are needed to prove it and show the clinical usefulness of the vaccine.
